EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eledon Pharmaceuticals's enterprise value is $-0.60 Mil.
Eledon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-42.63 Mil. Therefore, Eledon Pharmaceuticals's EV-to-EBITDA for today is 0.01.
The historical rank and industry rank for Eledon Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ELDN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -207.27 Med: 0 Max: 97.81
Current: 0.01
During the past 12 years, the highest EV-to-EBITDA of Eledon Pharmaceuticals was 97.81. The lowest was -207.27. And the median was 0.00.
ELDN's EV-to-EBITDA is ranked better than 93.01% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs ELDN: 0.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Eledon Pharmaceuticals's stock price is $2.16.
Eledon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.790. Therefore, Eledon Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Eledon Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Eledon Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eledon Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eledon Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eledon Pharmaceuticals's EV-to-EBITDA falls into.
Eledon Pharmaceuticals EV-to-EBITDA Calculation
Eledon Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Eledon Pharmaceuticals's current Enterprise Value is $-0.60 Mil.
Eledon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Eledon Pharmaceuticals's PE Ratio for today is calculated as:
Eledon Pharmaceuticals's share price for today is $2.16.
Eledon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.790.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Eledon Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Eledon Pharmaceuticals (Eledon Pharmaceuticals) Business Description
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELDN has been successfully added to your 